106047-29-4

Basic information

• Product Name: 6-Bromo-2-(pyridin-4-yl)pyridine
• Synonyms: 6-Bromo-2-(pyridin-4-yl)pyridine;2-bromo-6-(pyridin-4-yl)pyridine;6-broMo-2,4'-bipyridine;6-BroMo-2-(pyridin-4-yi)pyridine
• CAS NO: 106047-29-4
• Molecular Formula: C₁₀H₇BrN₂
• Molecular Weight: 235.083
• Mol File: 106047-29-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-Bromo-2-(pyridin-4-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-2-(pyridin-4-yl)pyridine(106047-29-4)
• EPA Substance Registry System: 6-Bromo-2-(pyridin-4-yl)pyridine(106047-29-4)

Safety Data

• Hazardous Substances Data: 106047-29-4(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-(pyridin-4-yl)pyridine is a chemical compound typically used in laboratory research settings. Its molecular formula is C10H6BrN2 and it has a molecular weight of 242.07 g/mol. This colored to light yellow or off-white solid compound is generally used as a chemical intermediate in the production of larger, more complex chemical structures, particularly in pharmaceutical and agrochemical research and development. Important to note that should be handled with care due to its potential hazardous effects when in direct contact.

Upstream product

• 626-05-1 2,6-Dibromopyridine 
• 93830-58-1 diethyl (pyridin-4-yl)borane 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 1313590-70-3 N-(3-methylphenyl)-6-(4-pyridinyl)-2-pyridinamine 
• 1191076-26-2 C₁₆H₁₁BrN₂ 

Relevant articles and documents

NOVEL COMPOUND WITH ELECTRON INJECTION AND/OR ELECTRON TRANSPORT CAPABILITIES AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

A compound represented by Formula 1 below and an organic light-emitting device including the compound are provided: Formula 1 Substituents in Formula 1 are the same as defined in the specification.

Organic light emitting device containing polycyclic heteroaryl compounds

A heterocyclic compound of general formula (1), an organic light-emitting device including the heterocyclic compound,and a flat panel display device including the organic light-emitting device are provided. The organic light-emitting devices using the heterocyclic compounds have high-efficiency, low driving voltage, high luminance and long lifespan: in which for example R4, R5, R6, R7, R8, R10 and R11 are hydrogen atoms, R1 and R9 are non-hydrogen substituent, and R2 and R3 are selected from methyl and phenyl groups.

SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells

We recently identified a class of pyridyl aniline thiazoles (PAT) that displayed selective cytotoxicity for von Hippel-Lindau (VHL) deficient renal cell carcinoma (RCC) cells in vitro and in vivo. Structure-activity relationship (SAR) studies were used to develop a comparative molecular field analysis (CoMFA) model that related VHL-selective potency to the three-dimensional arrangement of chemical features of the chemotype. We now report the further molecular alignment-guided exploration of the chemotype to discover potent and selective PAT analogues. The contribution of the central thiazole ring was explored using a series of five- and six-membered ring heterocyclic replacements to vary the electronic and steric interactions in the central unit. We also explored a positive steric CoMFA contour adjacent to the pyridyl ring using Pd-catalysed cross-coupling Suzuki-Miyaura, Sonogashira and nucleophilic displacement reactions to prepare of a series of aryl-, alkynyl-, alkoxy- and alkylamino-substituted pyridines, respectively. In vitro potency and selectivity were determined using paired RCC cell lines: the VHL-null cell line RCC4 and the VHL-positive cell line RCC4-VHL. Active analogues selectively induced autophagy in RCC4 cells. We have used the new SAR data to further develop the CoMFA model, and compared this to a 2D-QSAR method. Our progress towards realising the therapeutic potential of this chemotype as a targeted cytotoxic therapy for the treatment of RCC by exploiting the absence of the VHL tumour suppressor gene is reported.